Status
Regulatory status
Reviewed 5 October 2026
This changes often, and most suppliers never mention it. Below is where things stand, with the date of each development and a source you can read yourself. It is a summary, not legal advice, and it does not replace advice for your own market.
United States
- BPC-157, Ipamorelin
- Removed from FDA’s Category 2 list in April 2026. That removes the earlier safety-concern designation. It does not make them compoundable: FDA must still publish a proposed rule, take comments and publish a final rule, which is not expected before mid-to-late 2027. Supply as research material is unaffected.
- TB-500, KPV, MOTS-c, Epitalon, Semax
- Recommended by the Pharmacy Compounding Advisory Committee for the 503A bulk drug substances list. A recommendation is not permission, and the same rulemaking wait applies.
- Semaglutide, tirzepatide, liraglutide
- FDA has proposed permanently closing the compounding pathway for these. In March 2026 it issued 30 warning letters to telehealth companies over claims about compounded GLP-1s. Mossbench does not offer GLP-1 analogues.
- Any peptide over 40 amino acids
- Regulated as a biologic under the Public Health Service Act, which puts it outside the compounding question entirely.
Egypt
- Registration
- Pharmaceutical products must be registered with the Egyptian Drug Authority. Selling unregistered product carries penalties, and enforcement is active: in a single month’s campaign the EDA closed 85 unlicensed establishments across 17 governorates and seized goods valued above EGP 70 million.
- Import
- Importing finished products or raw materials requires EDA approval. An account importing into Egypt is approved against its own licence, and supply that cannot meet those requirements is declined.
- Advertising
- Advertising of health products is governed by Law 206/2017 and EDA Decree 590/2021. Advertising prescription-only medicines to the public is prohibited; materials aimed at healthcare professionals are permitted subject to EDA requirements.
- Research use
- Research-use material is not a route to clinical use. It does not meet the standard for compounding-pharmacy bulk ingredients, and it is not for administration to anyone.